The Pan American Association of Cannabinoid Medicine (APMC) is leading an innovative study to investigate the use of medicinal Cannabis in the treatment of osteoporosis and chronic pain in women, conditions that affect a significant number of women, especially after menopause.
The project, supported by R$ 284,428.00 from the 2024 parliamentary amendments public notice of the Parliamentary Front for Medicinal Cannabis, focuses on the study of bone biomarkers and genetic polymorphisms in CB2 and TRPV1 receptors, aiming to understand how these factors may influence the treatment of these conditions.

Genetic Polymorphisms and Treatment Personalization

The study goes beyond observing the effects of Cannabis on pain. The goal is also to evaluate its effects on bone metabolism and the participants’ quality of life, considering aspects such as sleep, anxiety, and cognitive functions.

Women will be monitored over the course of one year with quarterly exams of inflammatory biomarkers, bone densitometry, and genetic analyses, with a special focus on the genetic polymorphisms of the CB2 and TRPV1 receptors. These polymorphisms may determine the response to treatment, making the study relevant for precision medicine.

Women in Focus: The Impact of Menopause

Women are the main focus of the research, as they represent 80% of patients with chronic pain and 90% of osteoporosis cases. Menopause, with its hormonal changes, significantly increases the risk of these conditions.

It is important to explore Cannabis not only to relieve pain but also to improve the quality of life for women facing a combination of chronic pain, sleep disorders, and anxiety.

 

Academic Collaboration and Access Expansion

APMC’s study is being conducted in partnership with the Faculty of Medicine of ABC and the Presbyterian Mackenzie University, which contribute to a multidisciplinary environment for the development of the project.

The research goes beyond pain relief and seeks to understand how Cannabis can impact health more broadly. Additionally, the researchers hope that the results will help expand access to Cannabis treatments within the Unified Health System (SUS).

 

For more information about on medicial cannabis, ELS can help.

Please contact your local ELS consultant or email: info@elssolutions.pt

 

Contact us

We will contact you as soon as possible.